Hybridoma clone has been derived from hybridization of Sp2/0 myeloma cells with spleen cells of Balb/c mice immunized with conjugate FK-506-BSA.
MAb FK1 recognizes conjugated and non-conjugated FK-506 with apparent dissociation constant Kd=10⎺9 M.
IgM for MAb FK1
Detection of FK-506-antigen in ELISA.
FK 506 antigen is a novel macrolide with similar but more potent immunosuppressant activity than cyclosporine. FK 506 is used for primary or rescue immunosuppression in patients after solid organ transplantation. Clinically relevant FK506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK 506 blood levels than dosage; therefore therapeutic drug monitoring (TDM) of FK506 levels is a prerequisite for therapy. Whole blood is the matrix of choice for FK 506 TDM. The whole blood target level range aimed for in clinical practice is between 3.0 and 20.0 ng/ml and depends on the patient's liver function, the type of organ transplanted and the time after transplantation.
Euglobulin precipitation and dialysis.
50 mM Tris/HCl, 150 mM NaCl, pH 8.0, 0.09 % sodium azide (NaN₃)
+4 °C (+2 … +8 °C allowed)
This product is sold for research or further manufacturing use only. Standard Laboratory Practices should be followed when handling this material.
Product contains sodium azide as a preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling this product.
(Catalogue number and MAb: 4FK42-)